CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 6 outgoing, 6 incoming connections
- FinancialsHigh earnings quality
- Interpretations12 currently firing — 1 · 11
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.22%Below 5Y avg (2.82%)
Annual Rate
INR 7.00Paid annual
Payout Ratio
148.0%High
Payback Period
76.2 yr
Last Ex-Dividend
Jun 23, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
91.32BINR953.92M · vs all stocks (USD)
Trailing P/E
52.02xvs Diagnostics & Research peers
Revenue (TTM)
8.76BINR91.51M · vs all stocks (USD)
Profit Margin
20.13%vs Diagnostics & Research peers
Beta
0.4650xvs all stocks
52-Week Change
42.69%vs all stocks
Market Capitalization
91.32BINR953.92M · vs all stocks (USD)
Enterprise Value
90.53BINR945.70M · vs all stocks (USD)
Trailing P/E
52.02xvs Diagnostics & Research peers
Forward P/E
36.08xvs Diagnostics & Research peers
PEG Ratio
1.63xPrice to Sales (TTM)
10.42xvs Diagnostics & Research peers
Price to Book (MRQ)
15.60xvs Diagnostics & Research peers
Enterprise to Revenue
10.33xvs Diagnostics & Research peers
Enterprise to EBITDA
34.64xvs Diagnostics & Research peers
Gross Margin
74.10%vs Diagnostics & Research peers
Profit Margin
20.13%vs Diagnostics & Research peers
Operating Margin
26.99%vs Diagnostics & Research peers
Return on Assets (TTM)
21.82%vs Diagnostics & Research peers
Return on Equity (TTM)
27.82%vs Diagnostics & Research peers
Revenue (TTM)
8.76BINR91.51M · vs all stocks (USD)
Revenue per Share (TTM)
55.04INRUpdated Sep 23, 2026Quarterly Revenue Growth
24.30%vs Diagnostics & Research peers
Gross Profit (TTM)
4.82BINR50.30M · vs all stocks (USD)
EBITDA (TTM)
2.69BINR28.06M · vs all stocks (USD)
Net Income (TTM)
1.76BINR18.42M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
34.10%vs Diagnostics & Research peers
Operating Cash Flow (TTM)
2.13BINR22.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.63BINR17.03M · vs all stocks (USD)
Trailing Annual Dividend Rate
7.00INRUpdated Sep 23, 2026Trailing Annual Dividend Yield
1.22%vs all stocks
5-Year Average Dividend Yield
2.82%vs all stocks
Payout Ratio
148.04%vs Diagnostics & Research peers
Minority Interest (Equity)
5.20MINRFY2026 · Mar 31, 2026Revenue
8.22BINRFY2026 · Mar 31, 2026Cost of Goods Sold
2.20BINRFY2026 · Mar 31, 2026Gross Profit
6.02BINRFY2026 · Mar 31, 2026Operating Income
2.05BINR21.38M · vs all stocks (USD)
Pre-tax Income
2.13BINRFY2026 · Mar 31, 2026Income Tax Expense
500.30MINRFY2026 · Mar 31, 2026Net Income
1.63BINRFY2026 · Mar 31, 2026EBIT
2.16BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
2.69BINRFY2026 · Mar 31, 2026Selling, General & Administrative
942.00MINRFY2026 · Mar 31, 2026Other Operating Expenses
1.12BINRFY2026 · Mar 31, 2026Non-operating Interest Income
34.00MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
28.00MINRFY2026 · Mar 31, 2026EPS (Basic)
10.24INRFY2026 · Mar 31, 2026EPS (Diluted)
10.21INRFY2026 · Mar 31, 2026Basic Shares Outstanding
159.14MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
159.14MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
1.90MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
2.33BINRFY2026 · Mar 31, 2026Free Cash Flow
2.18BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
383.20MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
2.13BINRFY2026 · Mar 31, 2026Stock-based Compensation
240.90MINRFY2026 · Mar 31, 2026Other Non-cash Items
-3.70MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-9.90MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-22.30MINRFY2026 · Mar 31, 2026Capital Expenditures
-154.80MINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Purchase of Investments
-106.00MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-260.80MINRFY2026 · Mar 31, 2026Long-term Debt Payments
0.00INRFY2026 · Mar 31, 2026Common Dividends Paid
-1.48BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-1.48BINRFY2026 · Mar 31, 2026Shares Outstanding
159.16MSharesUpdated Sep 23, 2026Float Shares
77.96MSharesUpdated Sep 23, 2026% Held by Insiders
51.18%vs all stocks
% Held by Institutions
21.63%vs all stocks
Total Cash (MRQ)
1.90BINR19.83M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.93INRUpdated Sep 23, 2026Total Debt (MRQ)
506.90MINR5.30M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0865xvs Diagnostics & Research peers
Current Ratio (MRQ)
3.39xvs Diagnostics & Research peers
Book Value per Share (MRQ)
36.79INRUpdated Sep 23, 2026Total Assets
7.47BINR78.05M · vs all stocks (USD)
Total Current Assets
3.72BINRFY2026 · Mar 31, 2026Total Liabilities
1.61BINRFY2026 · Mar 31, 2026Total Non-current Assets
3.75BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
512.90MINRFY2026 · Mar 31, 2026Total Current Liabilities
1.10BINRFY2026 · Mar 31, 2026Cash
383.20MINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
383.20MINRFY2026 · Mar 31, 2026Other Short-term Investments
1.93BINRFY2026 · Mar 31, 2026Accounts Receivable
738.80MINRFY2026 · Mar 31, 2026Inventory
484.60MINRFY2026 · Mar 31, 2026Accounts Payable
653.70MINRFY2026 · Mar 31, 2026Short-term Debt
115.10MINRFY2026 · Mar 31, 2026Other Current Liabilities
40.50MINRFY2026 · Mar 31, 2026Long-term Debt
391.80MINRFY2026 · Mar 31, 2026Common Stock (Book)
1.59BINRFY2026 · Mar 31, 2026Retained Earnings
1.33BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
5.86BINR61.22M · vs all stocks (USD)
52-Week Low
342.55INRUpdated Sep 23, 202652-Week High
662.00INRUpdated Sep 23, 202652-Week Change
42.69%vs all stocks
Beta
0.4650xvs all stocks
50-Day MA
579.13INRUpdated Sep 23, 2026200-Day MA
477.98INRUpdated Sep 23, 2026Avg 10-Day Volume
244.13KSharesUpdated Sep 23, 2026Avg 30-Day Volume
534.89KSharesUpdated Sep 23, 2026Diluted EPS (TTM)
11.03INRUpdated Sep 23, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.24Receivables vs revenue divergence: 2.64
Financial Health
High earnings qualityNotable
Earnings Quality Score: 1.19
Supply Chain
Midstream position: 6 outgoing, 6 incoming connectionsNotable
Outgoing: 6.00Incoming: 6.00
High connectivity hub: 12 industry connectionsNotable
Total Connections: 12.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhuhai Enpower Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Bohai Automotive Systems Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Totech Corporation
Tier 1ProductionThroughput-Bound ConversionFlowRule
Sandur Manganese & Iron Ores Limited
Tier 1ProductionThroughput-Bound ConversionFlow
Zhejiang Grandwall Electric Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleFlow
Hunan Hualian China Industrial Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Jiangsu Zhenjiang New Energy Co. Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Suzhou Hailu Heavy Industry Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionRuleSenseMaking
Sk Ie Technology Co., Ltd.
Tier 1ProductionThroughput-Bound ConversionFlowRule
Johor Plantations Group Berhad
Tier 1ProductionThroughput-Bound ConversionFlowRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Catalyst Pharmaceuticals Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMAThree Asset-Base Ratios Elevated
Harmony Biosciences Holdings, Inc.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedCash Backing With OCF Coverage And Cash Near Total DebtThree Asset-Base Ratios Elevated
Games Workshop Group PLC
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Asset-Base Ratios Elevated